Therapeutic Effect of Chemotherapy Cycle in Nasopharyngeal Carcinoma (NPC) Patients Who Developed Bone-Only Metastasis

15 June 2020 : Clinical Research

Sikai Nong^1BCD, Xinbin Pan^1BCD, Kaihua Chen^1EF, Ye Li^1CD, Xiaodong Zhu^1AFG*

DOI: 10.12659/MSM.922244

Med Sci Monit 2020; 26:e922244

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Characteristics of the patient population.

Variables		N (%)
Age	>60	10 (17.2%)
Age	≤60	48 (82.8%)
Sex	Male	52 (89.7%)
Sex	Female	6 (10.3%)
Karnofsky performance status	≤80	10 (17.2%)
Karnofsky performance status	>80	48 (82.8%)
Histology (WHO)	Type I/II	18 (31.0%)
Histology (WHO)	Type III	40 (69.0%)
T stage	T1–2	18 (31.0%)
T stage	T3–4	40 (69.0%)
N stage	N0–1	10 (17.2%)
N stage	N2–3	48 (82.8%)
Number of bone metastatic sites	1	16 (27.6%)
	2	10 (17.2%)
	3	7 (12.1%)
	>3	25 (43.1%)
Nasopharyngeal radiotherapy	Yes	33 (56.9%)
Nasopharyngeal radiotherapy	No	25 (43.1%)
Chemotherapy regimen	TPF	51 (88.0%)
	PF	1 (1.7%)
	TP	1 (1.7%)
	Others	5 (8.6%)
TPF – docetaxel, cisplatin and 5-fluorouracil; PF – cisplatin and 5-fluorouracil; TP – docetaxel and cisplatin.

Back to the Article